The European Medicines Agency (EMA) has emphasized a recommendation that doctors should avoid using heparin to treat rare blood clots and low platelets in patients receiving AstraZeneca or Johnson & Johnson.
In a statement seeking to raise awareness of appropriate treatment, European medical regulators focused on the recommendations of the International Society for Thrombosis and Hemostasis (ISTH), which concluded that if vaccine-related coagulation is suspected, non-heparin should be started Anticoagulant.
EMA stated: “In order to deal with the suspicion (thrombocytopenia of thrombocytopenia syndrome), especially in the absence of local advice, the working group recommends that health professionals consider ISTH’s interim advice.”
The EMA’s recommendations emphasize the ISTH guidelines and are in line with the recommendations of the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC), which issued a strong warning about the use of heparin in this situation because it makes the condition worse. Alternative anticoagulants include Fondaparinux or Argatroban.